IL84407A - Tetrahydronaphthalene derivatives,their manufacture and pharmaceutical compositions containing them - Google Patents

Tetrahydronaphthalene derivatives,their manufacture and pharmaceutical compositions containing them

Info

Publication number
IL84407A
IL84407A IL84407A IL8440787A IL84407A IL 84407 A IL84407 A IL 84407A IL 84407 A IL84407 A IL 84407A IL 8440787 A IL8440787 A IL 8440787A IL 84407 A IL84407 A IL 84407A
Authority
IL
Israel
Prior art keywords
alkyl
dion
benzodiazepine
imidazo
interrupted
Prior art date
Application number
IL84407A
Other languages
English (en)
Other versions
IL84407A0 (en
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IL84407A0 publication Critical patent/IL84407A0/xx
Publication of IL84407A publication Critical patent/IL84407A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Hydrogenated Pyridines (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
  • Organic Insulating Materials (AREA)
  • Luminescent Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Steroid Compounds (AREA)
IL84407A 1986-11-14 1987-11-09 Tetrahydronaphthalene derivatives,their manufacture and pharmaceutical compositions containing them IL84407A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH456586 1986-11-14

Publications (2)

Publication Number Publication Date
IL84407A0 IL84407A0 (en) 1988-04-29
IL84407A true IL84407A (en) 1991-09-16

Family

ID=4278454

Family Applications (1)

Application Number Title Priority Date Filing Date
IL84407A IL84407A (en) 1986-11-14 1987-11-09 Tetrahydronaphthalene derivatives,their manufacture and pharmaceutical compositions containing them

Country Status (31)

Country Link
US (1) US4808605A (cs)
EP (1) EP0268148B1 (cs)
JP (1) JP2504490B2 (cs)
KR (1) KR960004863B1 (cs)
CN (1) CN1028991C (cs)
AT (1) ATE70267T1 (cs)
AU (1) AU600769B2 (cs)
BG (1) BG60937B2 (cs)
CA (1) CA1319144C (cs)
CS (2) CS264350B2 (cs)
DE (2) DE19775076I2 (cs)
DK (1) DK171349B1 (cs)
DZ (1) DZ1142A1 (cs)
ES (1) ES2040234T3 (cs)
FI (1) FI94414C (cs)
GR (1) GR3004029T3 (cs)
HK (1) HK110494A (cs)
HU (1) HU215915B (cs)
IE (1) IE60695B1 (cs)
IL (1) IL84407A (cs)
LV (1) LV5745B4 (cs)
MC (1) MC1883A1 (cs)
MX (1) MX173614B (cs)
NL (1) NL970019I2 (cs)
NO (2) NO172237C (cs)
NZ (1) NZ222474A (cs)
PH (1) PH23919A (cs)
PT (1) PT86130B (cs)
SG (1) SG114194G (cs)
ZA (1) ZA878362B (cs)
ZW (1) ZW20087A1 (cs)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2003283A1 (en) * 1988-12-05 1990-06-05 C. Anne Higley Imidazoles for the treatment of atherosclerosis
CA2011461A1 (en) * 1989-03-20 1990-09-20 Urs Hengartner Tetrahydronaphthalene derivatives
NL9001522A (nl) * 1990-07-04 1992-02-03 Schreiner Luchtvaart Werkwijze voor het vervaardigen van een voorwerp bestaande uit een schuimkern en eventueel een of meer afdeklagen.
TW216770B (cs) * 1991-07-23 1993-12-01 Hoffmann La Roche
US5250679A (en) * 1991-10-18 1993-10-05 Genentech, Inc. Nonpeptidyl platelet aggregation inhibitors having specificity for the GPIIb III.sub. receptor
US5565449A (en) * 1991-10-18 1996-10-15 Genentech, Inc. Nonpeptidyl integrin inhibitors having specificity for the GPIIb IIIa receptor
BR9509760A (pt) * 1994-11-23 1998-06-30 Neurogen Corp Composto
ATE215108T1 (de) 1995-06-23 2002-04-15 Univ Delft Tech Verfahren zur herstellung eines schäumbaren filmes
US5910606A (en) * 1996-01-31 1999-06-08 Hoffmann-La Roche Inc. Process for making α,β-unsaturated carboxylic acids
US5811556A (en) * 1997-04-30 1998-09-22 Roche Colorado Corporation Preparation of mibefradil via a naphthalenylacetic acid
US5811557A (en) * 1997-04-30 1998-09-22 Roche Colorado Corporation Preparation of mibefradil via an acetonitrile anion
US5808088A (en) * 1997-04-30 1998-09-15 Roche Colorado Corporation Preparation of mibefradil via an acetamide anion
US6897305B2 (en) * 1998-06-08 2005-05-24 Theravance, Inc. Calcium channel drugs and uses
US7101909B2 (en) * 1998-10-12 2006-09-05 Theravance, Inc. Calcium channel drugs and uses
DK1202986T3 (da) * 1999-07-28 2006-02-20 Ortho Mcneil Pharm Inc Amin- og amidderivater som ligander for neuropeptid Y-Y5-receptoren, der er nyttige ved behandlingen af obesitet og andre lidelser
AU2001235363A1 (en) * 2000-02-25 2001-09-03 Novo-Nordisk A/S Mibefradil analogues and their use
AU2001235364A1 (en) * 2000-02-25 2001-09-03 Novo-Nordisk A/S Tetrahydronaphtalene derivatives and their use
DE60124616T2 (de) * 2000-05-08 2007-09-13 Pfizer Products Inc., Groton Enzymatische Spaltung von selektiven Modulatoren des Östrogenrezeptors
FR2827862A1 (fr) * 2001-07-27 2003-01-31 Lipha Derives imidazolylalkylarylalcanoiques et leurs applications en therapeutique
EP1438297A1 (en) * 2001-10-10 2004-07-21 Aryx Therapeutics Mibefradil-based compounds as calcium channel blockers useful in the treatment of hypertension and angina
KR20030037081A (ko) * 2001-11-02 2003-05-12 한국과학기술연구원 Ｔ 타입 칼슘채널을 조절하여 복통을 억제하는 방법
BR0313593A (pt) 2002-08-19 2005-07-12 Pfizer Prod Inc Terapia de combinação para doenças hiperproliferativas
US20050037063A1 (en) * 2003-07-21 2005-02-17 Bolton Anthony E. Combined therapies
SG130192A1 (en) * 2003-07-28 2007-03-20 Janssen Pharmaceutica Nv Benzimidazole, benzthiazole and benzoxazole derivatives and their use as lta4h modulators
CA2574958A1 (en) * 2004-07-26 2006-02-09 Cotherix, Inc. Treatment of pulmonary hypertension by inhaled iloprost with a microparticle formulation
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
EP1951253A2 (en) * 2005-10-26 2008-08-06 Cotherix, Inc. Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
EP2351569B1 (en) 2005-10-26 2012-08-22 Asahi Kasei Pharma Corporation Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US7919506B2 (en) 2006-03-10 2011-04-05 Pfizer Inc. Dibenzyl amine compounds and derivatives
CN101663262B (zh) 2006-12-01 2014-03-26 百时美施贵宝公司 用于治疗动脉粥样硬化和心血管疾病的作为cetp抑制剂的n-(3-苄基)-2,2-(二苯基)-丙-1胺衍生物
TW200906396A (en) * 2007-02-14 2009-02-16 Janssen Pharmaceutica Nv LTA4H modulators and uses thereof
DK2152670T3 (en) * 2007-04-27 2014-02-24 Actelion Pharmaceuticals Ltd BROKEN SEX-LEADED RING CONNECTIONS
US7939527B2 (en) * 2008-04-11 2011-05-10 Janssen Pharmaceutica Nv Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase
WO2009130679A1 (en) * 2008-04-25 2009-10-29 Actelion Pharmaceuticals Ltd Benzimidazole derivatives as calcium channel blockers
EP2350021B1 (en) 2008-10-22 2013-03-20 Actelion Pharmaceuticals Ltd. Bridged tetrahydronaphthalene derivatives
WO2010046729A2 (en) * 2008-10-23 2010-04-29 Actelion Pharmaceuticals Ltd Tetrahydronaphthalene compounds
JP6205133B2 (ja) 2009-07-10 2017-09-27 プレジデント アンド フェローズ オブ ハーバード カレッジ 抗炎症剤としての恒久的に荷電したナトリウムおよびカルシウムチャンネルブロッカー
EP2542534A1 (en) * 2010-03-02 2013-01-09 Concert Pharmaceuticals Inc. Deuterated tetrahydronaphthalene derivatives
US8575361B2 (en) 2010-03-02 2013-11-05 Concert Pharmaceuticals Inc. Tetrahydronaphthalene derivatives
WO2012037665A1 (en) 2010-09-24 2012-03-29 Oral Delivery Technology Ltd. Nitric oxide releasing amino acid ester for treatment of pulmonary hypertension and other respiratory conditions
JP2016516804A (ja) 2013-04-17 2016-06-09 ファイザー・インク 心血管疾患を治療するためのｎ−ピペリジン−３−イルベンズアミド誘導体
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
WO2017070680A1 (en) 2015-10-22 2017-04-27 Cavion Llc Methods for treating angelman syndrome and related disorders
US11130750B2 (en) 2017-02-15 2021-09-28 Cavion, Inc. Calcium channel inhibitors
IL270180B (en) 2017-04-26 2022-06-01 Cavion Inc Methods to improve memory and cognition and to treat memory and cognition disorders
BR112021006398A2 (pt) 2018-10-03 2021-07-06 Cavion Inc tratamento de tremor essencial usando (r)-2-(4-isopropilfenil)-n-(1-(5-(2,2,2-trifluoretoxi)piridin-2-il)etil) acetamida
AU2020209215B2 (en) 2019-01-18 2023-02-02 Astrazeneca Ab PCSK9 inhibitors and methods of use thereof
CN115850119A (zh) * 2022-11-26 2023-03-28 南昌大学 一种2-氯芳香胺类化合物的合成方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3914216A (en) * 1962-12-18 1975-10-21 Boehringer Sohn Ingelheim 1-Phenyl-3H-1,4-benzodiazepine-2,5-(1H,4H)-diones
BE793460A (fr) * 1971-12-29 1973-06-28 Boehringer Sohn Ingelheim Nouvelles 1-aryl-3h,1,4-benzodiazepine-2,5-(1h
NZ213651A (en) * 1984-10-11 1989-07-27 Hoffmann La Roche Tetrahydronapthalene derivatives and medicaments

Also Published As

Publication number Publication date
NO874757L (no) 1988-05-16
FI94414B (fi) 1995-05-31
NO172237C (no) 1993-06-23
ATE70267T1 (de) 1991-12-15
US4808605A (en) 1989-02-28
AU600769B2 (en) 1990-08-23
CN87107875A (zh) 1988-05-25
HUT60251A (en) 1992-08-28
IL84407A0 (en) 1988-04-29
EP0268148B1 (de) 1991-12-11
DE19775076I2 (de) 2001-08-09
NO172237B (no) 1993-03-15
KR880006163A (ko) 1988-07-21
SG114194G (en) 1994-11-25
JP2504490B2 (ja) 1996-06-05
JPS63139171A (ja) 1988-06-10
NL970019I1 (nl) 1997-08-01
IE60695B1 (en) 1994-08-10
CA1319144C (en) 1993-06-15
PT86130B (pt) 1990-11-20
DK559987D0 (da) 1987-10-26
ZA878362B (en) 1988-05-16
CS394891A3 (en) 1992-06-17
NZ222474A (en) 1990-02-26
MX9271A (es) 1993-09-01
DK171349B1 (da) 1996-09-16
FI875024A7 (fi) 1988-05-15
DK559987A (da) 1988-05-15
CS787487A2 (en) 1988-11-15
DZ1142A1 (fr) 2004-09-13
HU215915B (hu) 1999-03-29
FI875024A0 (fi) 1987-11-13
PH23919A (en) 1990-01-23
MC1883A1 (fr) 1989-01-24
MX173614B (es) 1994-03-18
LV5745B4 (lv) 1996-12-20
FI94414C (fi) 1995-09-11
AU8090987A (en) 1988-05-19
IE873070L (en) 1988-05-14
EP0268148A1 (de) 1988-05-25
ZW20087A1 (en) 1988-07-20
NO874757D0 (no) 1987-11-13
NO1998001I1 (no) 1998-01-09
CS264350B2 (en) 1989-07-12
BG60937B2 (bg) 1996-06-28
LV5745A4 (lv) 1996-10-20
NL970019I2 (nl) 1997-11-03
PT86130A (en) 1987-12-01
DE3775177D1 (de) 1992-01-23
GR3004029T3 (cs) 1993-03-31
ES2040234T3 (es) 1993-10-16
CN1028991C (zh) 1995-06-21
KR960004863B1 (en) 1996-04-16
HK110494A (en) 1994-10-21

Similar Documents

Publication Publication Date Title
IL84407A0 (en) Tetrahydronaphthalene derivatives,their manufacture and pharmaceutical compositions containing them
NO176356C (no) Analogifremgangsmåte for fremstilling av nye terapeutisk aktive pyrazolopyridinforbindelser
IE780119L (en) IMIDAZO(1,2-a) QUINOLINE-2-CARBOXYLIC ACIDS
NO881835D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive bicykliske forbindelser.
IE44154L (en) 1,3,8-triazaspiro(4,5) decan-4-one derivatives
NO305655B1 (no) Antiarytmiske og kardiobeskyttende substituerte indenoylguanidiner, deres anvendelse for fremstilling av legemidler, samt legemiddel inneholdende disse
IE781226L (en) Antithrombatic compound
FI893570A0 (fi) Menetelmä lääkeaineina käyttökelpoisten 1H-imidatso/1,2-b/-pyratsolin johdannaisten valmistamiseksi
HUT42093A (en) Process for preparing 2-/2-thienyl/-imidazo/4,5-e/pyridine derivatives ang pharmaceutically acceptable acid addition salts thereof
JPS57131788A (en) 1,7-naphthyridine derivative
NO177786B (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive pyrido-[2,3-bÅ-benzazepin- (og -tiazepin)-5(6H)-on-derivater

Legal Events

Date Code Title Description
KB Patent renewed
KB Patent renewed